Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to ...

Vesicular monoamine transporter 2 (VMAT2) inhibitors are a type of medication used to manage a specific type of motor symptom in Huntington’s disease known as chorea. Chorea refers to the ...

The drug – which works as a beta blocker as well as inhibiting vesicular monoamine transporter 2 (VMAT2) – is already sold by Nippon Chemiphar as Calvan for the treatment of hypertension in ...